Method and kit for the classification and prognosis of tissue or organ fibrosis in a reparative or reactive process
AssigneesVivatech Company, Centre National de la Recherche Scientifique (CNRS), Universite Paris Diderot—Paris 7, Ecole Normale Superieure
InventorsClaire Dugast Darzacq, Xavier Darzacq, Maite Noizet, Emilie Lagoutte, Hugues Roest Crollius, Marlene Gratigny, Marielle Bouschbacher
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of diagnosis or prognosis of a tissue or organ fibrosis (e.g., skin fibrosis, hypertrophic scar or a keloid) in a reparative or reactive process comprising the step of determining the levels of expression of genes encoding different molecular markers in a sample of a tissue or organ from a mammalian, wherein different genes markers are studied.
Claims14
A method of diagnosis or prognosis of a tissue or organ susceptible of developing a fibrosis, such as a lung or skin fibrosis, comprising the step of determining the levels of expression of genes encoding different molecular markers in a sample of a tissue or organ from a mammalian, wherein said genes are defined as follows:
- at least one of the following genes show increased expression when compared with the expression in normal fibroblasts of said mammalian:
- EDIL3, EFHD1, FOXS1, HAPLN1, INHBA4, KRT16, MICAL2, PI16, POU2F2 and UCN2,
- or at least one of the following genes show decreased expression when compared with the expression in normal fibroblasts of said mammalian:
- APOD, CFB, CXCL1, KIT, MED12L, NR4A3, PTX3, RCAN2, STC1 and TFPI2.
A kit for determining the prognosis of mammalian wound which comprises:
- (1) A plurality of probes for detecting and quantifying the expression level of at least one RNA or protein of each one of the genes of table 1,
- (2) Optionally, reagents and instructions pertaining to the use of said probes.
A therapy consisting in decreasing the expression of PI16 in fibrosis, hypertrophic scar or keloid.
Dependencies are inferred from the claim text.